M&A advisors: "We've never seen such investor interest in this service before"

Danish and Nordic healthcare companies are sought after by specialized capital funds, with one particular segment having around 30 annual Nordic trades has garnered a lot of interest and sky-high valuations.

Photo: Colourbox

Denmark and Sweden have started to resemble battle grounds for global and highly specialized healthcare investors competing for the most attractive Nordic biotech and life science companies in the steadily growing markets of the future.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs